GRWD-5769 by Grey Wolf Therapeutics for Solid Tumor: Likelihood of Approval
GRWD-5769 is under clinical development by Grey Wolf Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData's report assesses how GRWD-5769's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.GRWD-5769 overviewGRWD-5769 is under development for the treatment of solid tumors including head and neck squamous cell carcinoma, cervical cancer, and hepatocellular carcinoma. It acts by targeting endoplasmic reticulum aminopeptidase 1 (ERAP1). It is administered through oral route.Grey Wolf Therapeutics overviewGrey Wolf Therapeutics, a drug discovery biotechnology company focused on immuno-oncology. For a complete picture of GRWD-5769's drug-specific PTSR and LoA scores, buy the report here.
GRWD-5769is under clinical development by Grey Wolf Therapeutics and currently in Phase II for Solid Tumor.
What's Your Reaction?
